Loading
When a screening test misses a cancer, we should know. Linking every negative result to the cancer registry and publishing what was missed, by stage, should be a condition of use.
Cervical and breast programmes audit interval cancers routinely; commercial blood tests do not. Propose that authorisation or reimbursement for MCED and single-cancer blood tests requires registry linkage of all negatives, with annual publication of stage-specific sensitivity, interval cancer rates, and test-negative cancers by subtype.
Shares Early detection of cancer, Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Early detection of cancer, Multi-cancer early detection (MCED), The hardest cancers are found late, Liquid biopsy (ctDNA).
Shares SEER (Surveillance, Epidemiology, and End Results), Real-world evidence, Weak real-world evidence and registries.
Shares Shield, Early detection of cancer, The hardest cancers are found late, Liquid biopsy (ctDNA).
Shares Early detection of cancer, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Shield, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Early detection of cancer, The hardest cancers are found late, Biomarkers are not validated or standardised.
Shares SEER (Surveillance, Epidemiology, and End Results), Early detection of cancer, The hardest cancers are found late.